Septerna: The SEP-479 Readout Could Unlock Further Upside

Septerna, Inc. is positioned for near-term value creation, with SEP-479 as the primary catalyst and a strong cash runway into 2029. SEP-479's Phase 1 readout in 1Q27 could provide the first meaningful clinical validation of SEPN's GPCR platform, with safety and key biomarker data in focus. SEP-204 is expected to enter Phase 1 in 1Q27, offering a differentiated oral approach for Graves' disease and thyroid eye disease with promising preclinical selectivity.